Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

SARS-CoV-2 Seroprevalence Trends in the Netherlands in the Variant of Concern Era: Input for Future Response.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • المصدر:
      Publisher: Wiley Country of Publication: England NLM ID: 101304007 Publication Model: Print Cited Medium: Internet ISSN: 1750-2659 (Electronic) Linking ISSN: 17502640 NLM ISO Abbreviation: Influenza Other Respir Viruses Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: Oxford, UK : Wiley, c2007-
    • الموضوع:
      COVID-19*/epidemiology ; COVID-19*/immunology ; SARS-CoV-2*/immunology ; Antibodies, Viral*/blood; Humans ; Seroepidemiologic Studies ; Netherlands/epidemiology ; Middle Aged ; Adolescent ; Adult ; Aged ; Child ; Child, Preschool ; Young Adult ; Male ; Female ; Aged, 80 and over ; Infant ; Prospective Studies ; COVID-19 Vaccines/immunology ; COVID-19 Vaccines/administration & dosage ; Immunoglobulin G/blood ; Vaccination/statistics & numerical data
    • نبذة مختصرة :
      Background: To inform future response planning we aimed to assess SARS-CoV-2 trends in infection- and/or vaccine-induced immunity, including breakthrough infections, among (sub)groups, professions and regions in the Dutch population during the Variant of Concern (VOC)-era.
      Methods: In this prospective population-based cohort, randomly selected participants (n = 9985) aged 1-92 years (recruited early-2020) donated home-collected fingerstick-blood samples at six timepoints in 2021/2022, covering waves dominated by Alpha, Delta, and multiple Omicron (sub-)variants. IgG antibody assessment against Spike-S1 and Nucleoprotein was combined with vaccination- and testing data to estimate infection-induced (inf) and total (infection- and vaccination-induced) seroprevalence.
      Results: Nationwide inf-seroprevalence rose modestly from 12% (95% CI 11-13) since Alpha to 26% (95% CI 24-28) amidst Delta, while total seroprevalence increased rapidly to 87% (95% CI 85-88), particularly in elderly and those with comorbidities (i.e., vulnerable groups). Interestingly, highest infection rates were noticeable among low/middle educated elderly, non-Western, those in contact professions, adolescents and young adults, and in low-vaccination coverage regions. Following Omicron emergence, inf-seroprevalence elevated sharply to 62% (95% CI 59-65) and further to 86% (95% CI 83-90) in late-2022, with frequent breakthrough infections and decreasing seroprevalence dissimilarities between most groups. Whereas > 90% of < 60-year-olds had been infected at least once, 30% of vaccinated vulnerable individuals had still not acquired hybrid immunity.
      Conclusions: Groups identified to have been infected disproportionally during the acute phase of the pandemic require specific attention in evaluation of control measures and future response planning worldwide. Furthermore, ongoing tailored vaccination efforts and (sero-)monitoring of vulnerable groups may remain important.
      (© 2024 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.)
    • References:
      Clin Infect Dis. 2021 Dec 16;73(12):2318-2321. (PMID: 33772265)
      Lancet Infect Dis. 2023 Jan;23(1):23-25. (PMID: 36463892)
      J Infect Dis. 2020 Oct 1;222(9):1452-1461. (PMID: 32766833)
      Sci Rep. 2023 Mar 30;13(1):5166. (PMID: 36997550)
      Sci Rep. 2023 Oct 26;13(1):18394. (PMID: 37884642)
      Vaccine. 2023 Jul 12;41(31):4488-4496. (PMID: 37328352)
      Euro Surveill. 2023 May;28(18):. (PMID: 37140450)
      PLoS Med. 2022 Nov 10;19(11):e1004107. (PMID: 36355774)
      Eur J Epidemiol. 2021 Jul;36(7):735-739. (PMID: 34114187)
      Am J Epidemiol. 1978 Jan;107(1):71-6. (PMID: 623091)
      Lancet Infect Dis. 2022 Jan;22(1):35-42. (PMID: 34461056)
      Euro Surveill. 2021 Jun;26(24):. (PMID: 34142653)
      Ann Intern Med. 2021 Mar;174(3):362-373. (PMID: 33253040)
      Lancet Infect Dis. 2023 May;23(5):556-567. (PMID: 36681084)
      EClinicalMedicine. 2023 Feb;56:101786. (PMID: 36590788)
      Lancet. 2022 Mar 5;399(10328):924-944. (PMID: 35202601)
      Euro Surveill. 2021 Feb;26(8):. (PMID: 33632374)
      Influenza Other Respir Viruses. 2023 Aug 22;17(8):e13174. (PMID: 37621921)
      Environ Res. 2024 Jul 1;252(Pt 1):118812. (PMID: 38561121)
      BMC Infect Dis. 2019 May 28;19(1):470. (PMID: 31138148)
      Qual Life Res. 2021 Oct;30(10):2795-2804. (PMID: 33991278)
      Lancet Public Health. 2021 Sep;6(9):e683-e691. (PMID: 34252364)
      Mucosal Immunol. 2024 Mar 27;:. (PMID: 38553008)
      J Epidemiol Community Health. 2020 Nov 28;:. (PMID: 33249407)
      Nat Commun. 2023 Aug 9;14(1):4793. (PMID: 37558656)
      Clin Infect Dis. 2021 Dec 16;73(12):2155-2162. (PMID: 33624751)
      Vaccines (Basel). 2023 Aug 24;11(9):. (PMID: 37766087)
      Euro Surveill. 2023 Jan;28(1):. (PMID: 36695447)
      Lancet Infect Dis. 2021 Nov;21(11):1507-1517. (PMID: 34171231)
      Vaccine. 2022 Apr 1;40(15):2251-2257. (PMID: 35287986)
      Lancet Infect Dis. 2023 Feb;23(2):150-152. (PMID: 36640796)
      Lancet Reg Health Eur. 2021 Jul;6:100127. (PMID: 34308409)
      Int J Infect Dis. 2022 Oct;123:104-111. (PMID: 35987470)
      Int J Infect Dis. 2023 Aug;133:36-42. (PMID: 37086863)
    • Grant Information:
      Ministry of Health, Welfare and Sport (VWS) in the Netherlands
    • Contributed Indexing:
      Keywords: COVID‐19; SARS‐CoV‐2; breakthrough infections; pandemic preparedness; prospective cohort; risk groups; seroprevalence trends; the Netherlands
    • الرقم المعرف:
      0 (Antibodies, Viral)
      0 (COVID-19 Vaccines)
      0 (Immunoglobulin G)
    • الموضوع:
      SARS-CoV-2 variants
    • الموضوع:
      Date Created: 20240605 Date Completed: 20240605 Latest Revision: 20240607
    • الموضوع:
      20240607
    • الرقم المعرف:
      PMC11150416
    • الرقم المعرف:
      10.1111/irv.13312
    • الرقم المعرف:
      38837866